There are disclosed pharmaceutically acceptable salts of tryptamine compounds, the use of such salt forms in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as those adapted for inhalation administration containing the salt forms, methods of delivering the pharmaceutically acceptable salt forms (e.g., via inhalation), and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders, with the salt forms. (Formula (I))
There are disclosed pharmaceutically acceptable salts of tryptamine compounds, the use of such salt forms in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as those adapted for inhalation administration containing the salt forms, methods of delivering the pharmaceutically acceptable salt forms (e.g., via inhalation), and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders, with the salt forms. (Formula (I))
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
There are disclosed deuterated 2C—X phenethylamine compounds. the use of such compounds in the treatment of diseases associated with a serotonin 5-HIT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds. methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.
C07C 323/32 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
C07C 217/60 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 323/20 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
22 receptor, such as anxiety disorders (e.g., separation anxiety, social anxiety, noise phobia, obsessive-compulsive disorder (OCD)) and depressive disorders.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for human use. Pharmaceutical research and development services; pharmaceutical drug development services; consultancy relating to pharmaceutical research and development; conducting early evaluations in the field of new pharmaceuticals; conducting clinical trials for pharmaceutical products; scientific research for medical and healthcare purposes; Product research and development in the field of major depressive disorders and other mental health disorders; Providing medical and scientific research information in the field of clinical trials.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for human use. Pharmaceutical research and development services; pharmaceutical drug development services; consultancy relating to pharmaceutical research and development; conducting early evaluations in the field of new pharmaceuticals; conducting clinical trials for pharmaceutical products; scientific research for medical and healthcare purposes; Product research and development in the field of major depressive disorders and other mental health disorders; Providing medical and scientific research information in the field of clinical trials.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for human use. Pharmaceutical research and development services; pharmaceutical drug development services; consultancy relating to pharmaceutical research and development; conducting early evaluations in the field of new pharmaceuticals; conducting clinical trials for pharmaceutical products; scientific research for medical and healthcare purposes; Product research and development in the field of major depressive disorders and other mental health disorders; Providing medical and scientific research information in the field of clinical trials.
Combination drag therapies comprising a 5-HTZA receptor agonist and an N-methyl-D-aspartate (NMDA) receptor antagonist (e.g., nitrous oxide, ketamine, etc.) are provided. Also described are pharmaceutical compositions and methods of treating a central nervous system (CNS) disorder or a psychiatric disease using the combination drug therapy, for example, via aerosol inhalation.
There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.
C07D 317/50 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 31/39 - Heterocyclic compounds having sulfur as a ring hetero atom having oxygen atoms in the same ring
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
C07D 277/68 - Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
11.
METHODS OF TREATING DEPRESSIVE DISORDERS WITH A PSILOCYBIN ANALOG
The present disclosure relates generally to methods of treating various diseases, disorders, and conditions, such as depressive disorders (e.g., Major Depressive Disorder (MDD)), substance use disorders, anxiety disorders, eating disorders, pain, and headache disorders via administration of deuterated psilocin and pharmaceutically acceptable salts, polymorphs, or solvates thereof.
Systems and methods are described that provide integrated user data collection devices for use in various therapies. The systems comprise a grip device with buttons to detect pressing patterns of a user. a mask device with one or more functional near infrared spectroscopy sensors, and a wearable device with biometric sensors. Alternatively. a camera module may be provided to record a video feed. The system is configured to transmit the data to a user device, which in turn is configured to provide a playback interface displaying the collected data. A device with a microphone, a speaker and an LED configuration illuminating a pattern based on a neurofeedback signal is also provided.
A61B 5/16 - Devices for psychotechnicsTesting reaction times
A61B 5/398 - Electrooculography [EOG], e.g. detecting nystagmusElectroretinography [ERG]
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
13.
METHODS OF TREATING DISORDERS WITH A PSILOCYBIN ANALOG
The present disclosure relates generally to methods of treating various diseases, disorders, and conditions, such as depressive disorders (e.g., Major Depressive Disorder (MDD)), substance use disorders, anxiety disorders, eating disorders, pain, and headache disorders via administration of deuterated psilocin and pharmaceutically acceptable salts, polymorphs, or solvates thereof.
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
The present disclosure relates to stable pharmaceutical compositions of amorphous psilocybin and deuterated psilocybin, and to the use of such pharmaceutical compositions in the treatment of diseases associated with a serotonin 5-HT2 receptor. The pharmaceutical compositions are formulated with solid dispersions of psilocybin or deuterated psilocybin in amorphous form dispersed in a polymer.
The present disclosure relates to psilocin compounds and pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT2 receptor agonists and uses in the treatment of diseases associated with a 5-HT2 receptor.
The present disclosure relates to psilocin compounds and pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT2 receptor agonists and uses in the treatment of diseases associated with a 5-HT2 receptor.
C07C 317/32 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
C07C 323/32 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
C07C 391/02 - Compounds containing selenium having selenium atoms bound to carbon atoms of six-membered aromatic rings
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 11/00 - Drugs for disorders of the respiratory system
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
2 2 receptor. The pharmaceutical compositions are formulated with solid dispersions of psilocybin or deuterated psilocybin in amorphous form dispersed in a polymer.
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
21.
METHODS FOR DELIVERY OF PSYCHEDELIC MEDICATIONS BY INHALATION AND SYSTEMS FOR PERFORMING THE METHODS
Provided are methods for delivering psychedelic drugs to a patient in need thereof comprising administering via inhalation of a psychedelic drug in the form of an aerosol, methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation of a psychedelic drug in the form of an aerosol, devices for delivery of psychedelic drug and nitrous oxide mixtures by inhalation, including with remote activation and control, and methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation of nitrous oxide/oxygen mixtures having an amount of nitrous oxide of 15 to 25% by volume of total gas.
Provided are methods for delivering psychedelic drugs such as tryptamine psychedelics to a patient in need thereof via inhalation. The psychedelic drug is delivered in the form of an aerosol, such as a mist or a dry powder. Methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation routes are provided.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
C07C 323/32 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
C07C 217/60 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 323/20 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
25.
COMBINATION OF NITROUS OXIDE AND 5-HT2A RECEPTOR AGONISTS
There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin receptor or monoamine transporter, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin receptor or monoamine transporter, such as inflammation, central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.
C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
C07C 217/08 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
C07D 317/58 - Radicals substituted by nitrogen atoms
C07C 217/60 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 323/32 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
C07C 391/02 - Compounds containing selenium having selenium atoms bound to carbon atoms of six-membered aromatic rings
C07B 59/00 - Introduction of isotopes of elements into organic compounds
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
The present disclosure relates to pharmaceutical compositions formulated with psilocin and/or deuterated psilocin compounds or pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, and an organic acid agent as a pharmaceutically acceptable vehicle. Uses in the treatment of diseases, such as those associated, with a 5-HT2 receptor, are also disclosed.
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
32.
FORMULATIONS OF PSILOCYBIN ANALOGS AND METHODS OF USE
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07B 59/00 - Introduction of isotopes of elements into organic compounds
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
33.
DEUYERATED TRYPTAMINE DERIVATIVE FORMULATIONS AND METHODS OF USE
The present disclosure is directed to pharmaceutical compositions and to the use of such formulations in the treatment of diseases associated with a serotonin 5-HT2 receptor.
Combination drag therapies comprising a 5-HTZA receptor agonist and an N-methyl-D-aspartate (NMDA) receptor antagonist (e.g., nitrous oxide, ketamine, etc.) are provided. Also described are pharmaceutical compositions and methods of treating a central nervous system (CNS) disorder or a psychiatric disease using the combination drug therapy, for example, via aerosol inhalation.
NN-methyl-D-aspartate (NMDA) receptor antagonist (e.g., nitrous oxide, ketamine, etc.) are provided. Also described are pharmaceutical compositions and methods of treating a central nervous system (CNS) disorder or a psychiatric disease using the combination drug therapy, for example, via aerosol inhalation.
Systems and methods are described that provide integrated user data collection devices for use in various therapies. The systems comprise a grip device (122) with buttons to detect pressing patterns of a user, a mask device (126) with one or more functional near infrared spectroscopy sensors (140), and a wearable device (120) with biometric sensors. Alternatively, a camera module may be provided to record a video feed. The system is configured to transmit the data to a user device (102), which in turn is configured to provide a playback interface (118) displaying the collected data. A device with a microphone (128), a speaker (130)) and an LED configuration (142) illuminating a pattern based on a neurofeedback signal is also provided.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
A61B 5/021 - Measuring pressure in heart or blood vessels
22 receptor. The pharmaceutical compositions are formulated with solid dispersions of psilocybin or deuterated psilocybin in amorphous form dispersed in a polymer.
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/04 - Centrally acting analgesics, e.g. opioids
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
The present disclosure relates to stable pharmaceutical compositions of amorphous psilocybin and deuterated psilocybin, and to the use of such pharmaceutical compositions in the treatment of diseases associated with a serotonin 5-HT2 receptor. The pharmaceutical compositions are formulated with solid dispersions of psilocybin or deuterated psilocybin in amorphous form dispersed in a polymer.
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
40.
PSILOCYBIN ANALOGS, SALTS, COMPOSITIONS, AND METHODS OF USE
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07B 59/00 - Introduction of isotopes of elements into organic compounds
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
41.
PSILOCYBIN ANALOGS, SALTS, COMPOSITIONS, AND METHODS OF USE
The present disclosure relates to psilocin compounds and pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT2 receptor agonists and uses in the treatment of diseases associated with a 5-HT2 receptor.
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
42.
Deuterated tryptamine derivatives and methods of use
Provided are methods for delivering psychedelic drugs to a patient in need thereof comprising administering via inhalation of a psychedelic drug in the form of an aerosol, methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation of a psychedelic drug in the form of an aerosol, devices for delivery of psychedelic drug and nitrous oxide mixtures by inhalation, including with remote activation and control, and methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation of nitrous oxide/oxygen mixtures having an amount of nitrous oxide of 15 to 25% by volume of total gas.
Provided are methods for delivering psychedelic drugs to a patient in need thereof comprising administering via inhalation of a psychedelic drug in the form of an aerosol, methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation of a psychedelic drug in the form of an aerosol, devices for delivery of psychedelic drug and nitrous oxide mixtures by inhalation, including with remote activation and control, and methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation of nitrous oxide/oxygen mixtures having an amount of nitrous oxide of 15 to 25% by volume of total gas.
There are disclosed deuterated 2C-X phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.
C07C 321/28 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61P 25/00 - Drugs for disorders of the nervous system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07C 217/60 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
48.
PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE
There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
